Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 1/20 | 0.53 |
| ▸ | TYK2 | P29597 | 6/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527970 | 0.88 | CSNK2B (0.53) | CSNK2BTYK2STAT3 | |
| SCHEMBL1527969 | 0.88 | CSNK2B (0.53) | CSNK2BTYK2STAT3 | |
| SCHEMBL1527858 | 0.87 | CSNK2B (0.52) | CSNK2BPIK3CAP2RX7 | |
| SCHEMBL1527822 | 0.85 | CSNK2B (0.55) | CSNK2B | |
| SCHEMBL1527900 | 0.85 | CSNK2B (0.63) | CSNK2BTYK2PIK3CA | |
| SCHEMBL1487852 | 0.85 | CSNK2B (0.74) | CSNK2BTYK2 | |
| SCHEMBL1528093 | 0.84 | CSNK2B (0.50) | CSNK2BTYK2STAT3P2RX7 | |
| SCHEMBL12769153 | 0.84 | CSNK2B (0.50) | CSNK2BTYK2STAT3PIK3CAP2RX7 | |
| SCHEMBL12768865 | 0.84 | CSNK2B (0.50) | CSNK2BTYK2STAT3P2RX7 | |
| SCHEMBL1527855 | 0.82 | CSNK2B (0.57) | CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | PIM2, PIM1, PIM3 | CSNK2B 17/4885TYK2 39/4885STAT3 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.